Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Valneva, Marinomed (18/09/2024)

22.09.2024

Valneva: Valneva, a specialty vaccine company, announced that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to potentially expand the use of its chikungunya vaccine, IXCHIQ®, to adolescents aged 12 to 17 years in Europe and Canada. The Canadian label extension application also includes two-year antibody persistence data, which is a key differentiator for IXCHIQ® that was already included in the initial EMA filing. Valneva expects to submit data to the U.S. Food and Drug Administration (FDA) this year to also support potential label extensions in the U.S.
Valneva: weekly performance: -17.94%

Marinomed: Marinomed Biotech AG has resolved to increase the Company's share capital by EUR 154,053. The issue price per new share is EUR 5, so that the total issue price amounts to EUR 770,265. All 154,053 new shares have been subscribed at these issue terms and conditions by a total of eleven investors, including members of the Supervisory and Management Boards. The Company is continuing to negotiate with another investor regarding a possible second capital increase of a further 154,053 new shares.
Marinomed Biotech: weekly performance: -9.39%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (18/09/2024)


Partners









latest 21st Austria

21st Austria weekly - Valneva, Marinomed (18/09/2024)


22.09.2024, 1292 Zeichen



Valneva: Valneva, a specialty vaccine company, announced that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to potentially expand the use of its chikungunya vaccine, IXCHIQ®, to adolescents aged 12 to 17 years in Europe and Canada. The Canadian label extension application also includes two-year antibody persistence data, which is a key differentiator for IXCHIQ® that was already included in the initial EMA filing. Valneva expects to submit data to the U.S. Food and Drug Administration (FDA) this year to also support potential label extensions in the U.S.
Valneva: weekly performance: -17.94%

Marinomed: Marinomed Biotech AG has resolved to increase the Company's share capital by EUR 154,053. The issue price per new share is EUR 5, so that the total issue price amounts to EUR 770,265. All 154,053 new shares have been subscribed at these issue terms and conditions by a total of eleven investors, including members of the Supervisory and Management Boards. The Company is continuing to negotiate with another investor regarding a possible second capital increase of a further 154,053 new shares.
Marinomed Biotech: weekly performance: -9.39%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (18/09/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #775: ATX nach US-Wahlen fester, Less Taxes fürs Stammbuch, Top-Tag für Kontron unabhängig von Trump




 

Bildnachweis

Aktien auf dem Radar:Warimpex, Andritz, RBI, Immofinanz, Austriacard Holdings AG, Addiko Bank, Strabag, EuroTeleSites AG, EVN, Mayr-Melnhof, Frequentis, CA Immo, Polytec Group, AT&S, Gurktaler AG Stamm, Linz Textil Holding, Marinomed Biotech, Porr, RWT AG, SBO, Verbund, voestalpine, Oberbank AG Stamm, Zumtobel, Palfinger, Agrana, Amag, Flughafen Wien, OMV, Österreichische Post, Rosenbauer.


Random Partner

Montana Aerospace
Montana Aerospace zählt dank ihrer globalen Präsenz in Entwicklung und Fertigung sowie ihrer Multimaterial-Kompetenz zu den weltweit führenden Herstellern von komplexen Leichtbaukomponenten und Strukturen für die Luftfahrtindustrie. Als hochgradig integrierter Komplettanbieter mit State-of-the-Art-Fertigungsstätten in Europa, Amerika und Asien unterstützen wir die Local-to-Local-Strategie unserer Kunden.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten